These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23078038)

  • 21. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
    Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
    Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].
    Li J; Zeng LJ; Zhao Y; Su C; Huang BH
    Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):543-7. PubMed ID: 19954643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone.
    Gotoh M; Kitahara T; Sakuta J; Akahane D; Ohyashiki K
    Leuk Res; 2010 Apr; 34(4):e120-1. PubMed ID: 19875167
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma.
    Tokuhira M; Watanabe R; Nemoto T; Hanzawa K; Sagawa M; Tomikawa T; Mori S; Kizaki M
    Leuk Res; 2011 May; 35(5):591-7. PubMed ID: 21167601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
    Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
    Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chemotherapy for multiple myeloma].
    Ishida T
    Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
    Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multiple myeloma].
    Iida S
    Rinsho Ketsueki; 2012 Feb; 53(2):155-63. PubMed ID: 22450574
    [No Abstract]   [Full Text] [Related]  

  • 30. Bortezomib induced a phrenic palsy in a multiple myeloma patient.
    Nizeica V; Collet P; Marotte H
    Ann Hematol; 2013 Aug; 92(8):1135-6. PubMed ID: 23370597
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
    Gozzetti A; Defina M; Bocchia M; Fabbri A; Marchini E; Chitarrelli I; Lauria F
    Leuk Res; 2010 Nov; 34(11):e288-9. PubMed ID: 20557933
    [No Abstract]   [Full Text] [Related]  

  • 32. Bortezomib dosing in relapsed multiple myeloma.
    Jagannath S
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):101-2. PubMed ID: 17026818
    [No Abstract]   [Full Text] [Related]  

  • 33. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
    Minarik J; Pika T; Bacovsky J; Langova K; Scudla V
    Br J Haematol; 2012 Oct; 159(1):111-3. PubMed ID: 22816982
    [No Abstract]   [Full Text] [Related]  

  • 35. Update on recent developments for patients with newly diagnosed multiple myeloma.
    Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
    Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimising bortezomib in newly diagnosed multiple myeloma.
    Rajkumar SV
    Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
    Richardson P; Schlag R; Khuageva N; Dimopoulos M; Shpilberg O; Kropff M; Vekemans MC; Petrucci MT; Rossiev V; Hou J; Robak T; Mateos MV; Anderson K; Esseltine DL; Cakana A; Liu K; Deraedt W; van de Velde H; San Miguel JF
    Br J Haematol; 2011 Apr; 153(2):212-21. PubMed ID: 21375521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bortezomib-based triple combinations (VCD, PAD) for untreated patients with multiple myeloma].
    Izumi T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():646-8. PubMed ID: 25831840
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
    Reeder CB; Reece DE; Kukreti V; Mikhael JR; Chen C; Trudel S; Laumann K; Vohra H; Fonseca R; Bergsagel PL; Leis JF; Tiedemann R; Stewart AK
    Br J Haematol; 2014 Nov; 167(4):563-5. PubMed ID: 24974945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.